{"id":"bimatoprost-sustained-release-implant","safety":{"commonSideEffects":[{"rate":"null","effect":"Conjunctival hyperemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bimatoprost is a selective FP receptor agonist that reduces aqueous humor production, leading to decreased intraocular pressure. This sustained release implant provides a long-term solution for glaucoma treatment.","oneSentence":"Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:58.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of glaucoma"}]},"trialDetails":[{"nctId":"NCT07154797","phase":"NA","title":"Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma","status":"COMPLETED","sponsor":"SpyGlass Pharma, Inc.","startDate":"2022-04-21","conditions":"Cataract, Ocular Hypertension, Glaucoma","enrollment":24},{"nctId":"NCT07154810","phase":"","title":"Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2023-03-16","conditions":"Glaucoma, Cataract, Ocular Hypertension","enrollment":23},{"nctId":"NCT05338606","phase":"","title":"Expanded Access to Bimatoprost (Durysta)","status":"NO_LONGER_AVAILABLE","sponsor":"AbbVie","startDate":"","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT02507687","phase":"PHASE3","title":"Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-27","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":240},{"nctId":"NCT04285580","phase":"PHASE3","title":"A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-06-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AGN-192024","Durysta"],"phase":"phase_2","status":"active","brandName":"Bimatoprost Sustained Release Implant","genericName":"Bimatoprost Sustained Release Implant","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure. Used for Treatment of glaucoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}